The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Katsuyuki Hotta

Department of Respiratory Medicine

Okayama University Hospital

2-5-1

Shikata-cho

Japan

[email]@md.okayama-u.ac.jp

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Respiratory Medicine, Okayama University Hospital, 2-5-1, Shikata-cho, Japan. 2004 - 2010
  • Health and Medical Section, Health and Environmental Center, Okayama University, Tsushima-Naka, Japan. 2005 - 2007
  • Department of Hematology, Oncology and Respiratory Medicine, Graduate School of Medicine and Dentistry, Okayama University, Japan. 2004
  • Division of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. 2003

References

  1. Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Hotta, K., Kiura, K., Takigawa, N., Suzuki, E., Yoshioka, H., Okada, T., Kishino, D., Ueoka, H., Inoue, K., Tabata, M., Tanimoto, M. Lung. Cancer (2010) [Pubmed]
  2. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience. Hotta, K., Kiura, K., Takigawa, N., Yoshioka, H., Harita, S., Kuyama, S., Yonei, T., Fujiwara, K., Maeda, T., Aoe, K., Ueoka, H., Kamei, H., Umemura, S., Moritaka, T., Segawa, Y., Kawai, H., Bessho, A., Kato, K., Tabata, M., Tanimoto, M. J. Thorac. Oncol (2010) [Pubmed]
  3. Desire for information and involvement in treatment decisions: lung cancer patients' preferences and their physicians' perceptions: results from Okayama Lung Cancer Study Group Trial 0705. Hotta, K., Kiura, K., Takigawa, N., Yoshioka, H., Hayashi, H., Fukuyama, H., Nishiyama, A., Yokoyama, T., Kuyama, S., Umemura, S., Kato, Y., Nogami, N., Segawa, Y., Yasugi, M., Tabata, M., Tanimoto, M. J. Thorac. Oncol (2010) [Pubmed]
  4. Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. Hotta, K., Fujiwara, Y., Matsuo, K., Kiura, K., Takigawa, N., Tabata, M., Tanimoto, M. J. Thorac. Oncol (2009) [Pubmed]
  5. Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience. Hotta, K., Kiura, K., Takigawa, N., Kuyama, S., Segawa, Y., Yonei, T., Gemba, K., Aoe, K., Shibayama, T., Matsuo, K., Kamei, H., Fujiwara, Y., Bessho, A., Moritaka, T., Sugimoto, K., Tabata, M., Ueoka, H., Tanimoto, M. J. Cancer Res. Clin. Oncol. (2009) [Pubmed]
  6. Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer. Hotta, K., Kiura, K., Fujiwara, Y., Takigawa, N., Oze, I., Ochi, N., Tabata, M., Tanimoto, M. Ann. Oncol. (2009) [Pubmed]
  7. Association of the benefit from gefitinib monotherapy with smoking status in Japanese patients with non-small-cell lung cancer. Hotta, K., Kiura, K., Takigawa, N., Fujiwara, Y., Tabata, M., Ueoka, H., Tanimoto, M. Lung. Cancer (2008) [Pubmed]
  8. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. Hotta, K., Fujiwara, Y., Matsuo, K., Suzuki, T., Kiura, K., Tabata, M., Takigawa, N., Ueoka, H., Tanimoto, M. Cancer (2007) [Pubmed]
  9. Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer. Hotta, K., Kiura, K., Toyooka, S., Takigawa, N., Soh, J., Fujiwara, Y., Tabata, M., Date, H., Tanimoto, M. J. Thorac. Oncol (2007) [Pubmed]
  10. Role of early serial change in serum carcinoembryonic antigen levels as a predictive marker for radiological response to gefitinib in Japanese patients with non-small cell lung cancer. Hotta, K., Kiura, K., Tabata, M., Takigawa, N., Fujiwara, Y., Umemura, S., Tanimoto, M. Anticancer Res. (2007) [Pubmed]
  11. An intensive group therapy programme for smoking cessation using nicotine patch and internet mailing supports in a university setting. Hotta, K., Kinumi, K., Naito, K., Kuroki, K., Sakane, H., Imai, A., Kobayashi, M., Ohnishi, M., Ogura, T., Miura, H., Takahashi, Y., Tobe, K. Int. J. Clin. Pract. (2007) [Pubmed]
  12. Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation. Hotta, K., Tabata, M., Kiura, K., Kozuki, T., Hisamoto, A., Katayama, H., Takigawa, N., Fujimoto, N., Fujiwara, K., Ueoka, H., Tanimoto, M. Oncol. Rep. (2007) [Pubmed]
  13. Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. Hotta, K., Fujiwara, Y., Kiura, K., Takigawa, N., Tabata, M., Ueoka, H., Tanimoto, M. J. Thorac. Oncol (2007) [Pubmed]
  14. Whole blood interferon-gamma assay for baseline tuberculosis screening among Japanese healthcare students. Hotta, K., Ogura, T., Nishii, K., Kodani, T., Onishi, M., Shimizu, Y., Kanehiro, A., Kiura, K., Tanimoto, M., Tobe, K. PLoS. ONE (2007) [Pubmed]
  15. Advances in our understanding of postoperative adjuvant chemotherapy in resectable non-small-cell lung cancer. Hotta, K., Matsuo, K., Kiura, K., Ueoka, H., Tanimoto, M. Curr. Opin. Oncol (2006) [Pubmed]
  16. New cytotoxic agents: a review of the literature. Hotta, K., Ueoka, H. Crit. Rev. Oncol. Hematol. (2005) [Pubmed]
  17. Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer. Hotta, K., Takigawa, N., Kiura, K., Tabata, M., Umemura, S., Ogino, A., Uchida, A., Bessho, A., Segawa, Y., Shinkai, T., Nogami, N., Harita, S., Okimoto, N., Ueoka, H., Tanimoto, M. Anticancer Res. (2005) [Pubmed]
  18. Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Hotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M., Harita, S., Gemba, K., Yonei, T., Bessho, A., Tanimoto, M. Ann. Oncol. (2005) [Pubmed]
  19. Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Hotta, K., Ueoka, H., Kiura, K., Tabata, M., Ogino, A., Umemura, S., Harita, S., Gemba, K., Yonei, T., Bessho, A., Maeda, T., Tanimoto, M. Acta. Oncol (2005) [Pubmed]
  20. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Hotta, K., Kiura, K., Tabata, M., Harita, S., Gemba, K., Yonei, T., Bessho, A., Maeda, T., Moritaka, T., Shibayama, T., Matsuo, K., Kato, K., Kanehiro, A., Tanimoto, Y., Matsuo, K., Ueoka, H., Tanimoto, M. Cancer. J (2005) [Pubmed]
  21. A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer. Hotta, K., Ueoka, H., Kiura, K., Tabata, M., Kuyama, S., Satoh, K., Kozuki, T., Hisamoto, A., Hosokawa, S., Fujiwara, K., Tanimoto, M. Lung. Cancer (2004) [Pubmed]
  22. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. Hotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M., Tanimoto, M. J. Clin. Oncol. (2004) [Pubmed]
  23. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. Hotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M., Tanimoto, M. J. Clin. Oncol. (2004) [Pubmed]
  24. An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced non-small cell lung cancer. Hotta, K., Ueoka, H., Kiura, K., Tabata, M., Tanimoto, M. Lung. Cancer (2004) [Pubmed]
  25. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Hotta, K., Kiura, K., Ueoka, H., Tabata, M., Fujiwara, K., Kozuki, T., Okada, T., Hisamoto, A., Tanimoto, M. Lung. Cancer (2004) [Pubmed]
  26. Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials. Hotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M., Tanimoto, M. Ann. Oncol. (2004) [Pubmed]
  27. Distant failure after treatment of postoperative locoregional recurrence of non-small cell lung cancer. Hotta, K., Sekine, I., Suzuki, K., Kondo, H., Asamura, H., Sumi, M., Yamamoto, N., Kunitoh, H., Ohe, Y., Tamura, T., Kodama, T., Saijo, N., Tsuchiya, R. Thorac. Cardiovasc. Surg (2003) [Pubmed]
 
WikiGenes - Universities